Rheumatoid Arthritis Market Insights, Epidemiology and Market Forecast-2030
DelveInsight launched a new report on Rheumatoid Arthritis Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report1. One in 12 women and 1 in 20 men will develop an inflammatory autoimmune rheumatic disease during their lifetime.2. About 1.5 million in the US have Rheumatoid Arthritis with a prevalence of 0.6%.
Key benefits of the report1. Rheumatoid Arthritis market report covers a descriptive overview and comprehensive insight of the Rheumatoid Arthritis epidemiology and Rheumatoid Arthritis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Rheumatoid Arthritis market report provides insights on the current and emerging therapies.3. Rheumatoid Arthritis market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Rheumatoid Arthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rheumatoid Arthritis market.
Request for sample pages
“Women are affected by Rheumatoid Arthritis three times more than men.”
Rheumatoid Arthritis treatment landscape has progressed from the last two decade, including the diagnosis and treatment. Albeit, presently there is no cure for the disease, the goals of therapy are to decrease pain, inflammation control, preserve the ability of the patient to function in activities of daily living and work and avert joint destruction. Pharmacists and other healthcare professionals play a vital role in caring for Rheumatoid Arthritis patients. The pharmacologic approaches have relied on combinations of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids (prednisone, methylprednisone), disease-modifying anti-rheumatic drugs (DMARDs) and biologics.
Corticosteroids, including prednisone, prednisolone and methylprednisolone, are potent and quick-acting anti-inflammatory medications. They may be used to get potentially damaging inflammation under control and may be needed to control severe polyarticular disease until disease-modifying antirheumatic drugs (DMARDs) have been added and become useful.There is now a better comprehension of the mechanisms/pathways involved in the disease, permitting site-specific drug development. There are two major types of Disease-Modifying Antirheumatic Drugs (DMARDs): biological and synthetic.
Conventional, synthetic DMARDs (csDMARDs) are not site-specific, and they do not have precise mechanisms of action for relieving the disease. Synthetic DMARDs targets to a particular site. Biological DMARDs are also site-specific (e.g., targeting TNF, IL-6, IL-1, B cells, or T cells).
The launch of the emerging therapies is expected to significantly impact Rheumatoid Arthritis treatment scenario in the upcoming years:-Drugs covered1. Filgotinib2. OlokizumabAnd many others
The key players in Rheumatoid Arthritis market are:1. Galapagos NV/Gilead Sciences2. R-PharmAnd many others
Table of contents1. Report Introduction2. Rheumatoid Arthritis Market Overview at a Glance3. Rheumatoid Arthritis Disease Background and Overview4. Rheumatoid Arthritis Epidemiology and Patient Population5. Rheumatoid Arthritis Country-Wise Epidemiology6. United States7. EU–5 Countries7.1. Assumptions and Rationale7.2. Germany7.3. France7.4. Italy7.5. Spain7.6. United Kingdom7.7. Japan8. Rheumatoid Arthritis Treatments and Medical Practices9. Rheumatoid Arthritis Emerging Therapies10. Key Cross Competition10.1. Filgotinib: Galapagos NV/Gilead Sciences10.2. Olokizumab: R-Pharm11. Rheumatoid Arthritis Market Size12. 7MM Rheumatoid Arthritis Country-Wise Market Analysis13. United States Market Size14. EU5 Market Size14.1. Germany Market Size14.2. France Market Size14.3. Italy Market Size14.4. Spain Market Size14.5. UK Market Size15. Japan Market Size16. Rheumatoid Arthritis Report Methodology17. DelveInsight Capabilities18. Disclaimer19. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
[email protected]+919650213330SOURCE DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/